Amundi Has $275.31 Million Position in Bristol Myers Squibb Company $BMY

Amundi grew its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 9.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,780,139 shares of the biopharmaceutical company’s stock after purchasing an additional 513,255 shares during the quarter. Amundi’s holdings in Bristol Myers Squibb were worth $275,308,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the business. New England Asset Management Inc. raised its holdings in shares of Bristol Myers Squibb by 0.8% during the first quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company’s stock valued at $2,408,000 after purchasing an additional 305 shares during the period. Commonwealth Retirement Investments LLC increased its position in Bristol Myers Squibb by 24.6% in the 2nd quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after buying an additional 11,690 shares in the last quarter. Norges Bank acquired a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $1,554,154,000. Sound View Wealth Advisors Group LLC boosted its holdings in Bristol Myers Squibb by 438.0% in the second quarter. Sound View Wealth Advisors Group LLC now owns 307,849 shares of the biopharmaceutical company’s stock worth $14,250,000 after acquiring an additional 250,624 shares in the last quarter. Finally, Wealth Quarterback LLC boosted its holdings in Bristol Myers Squibb by 42.6% in the second quarter. Wealth Quarterback LLC now owns 25,443 shares of the biopharmaceutical company’s stock worth $1,178,000 after acquiring an additional 7,603 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BMY. Scotiabank reaffirmed a “sector perform” rating and set a $53.00 target price (up from $45.00) on shares of Bristol Myers Squibb in a research report on Thursday. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Truist Financial set a $65.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday. Finally, Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Four research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $55.25.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $52.16 on Friday. The company has a fifty day moving average price of $46.21 and a 200-day moving average price of $46.78. The firm has a market cap of $106.18 billion, a price-to-earnings ratio of 17.62, a PEG ratio of 7.95 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same period last year, the firm earned $1.80 earnings per share. The firm’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, equities research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date was Friday, October 3rd. Bristol Myers Squibb’s payout ratio is presently 83.78%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.